A 2-part Phase 2 Study of Safety, Pharmacokinetics and Biomarkers in Children With Duchenne Muscular Dystrophy Including a Randomized, Double-Blind, Placebo-Controlled Part A, Followed by an Open-Label Part B
Latest Information Update: 16 Feb 2024
At a glance
- Drugs Sevasemten (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms LYNX
- Sponsors Edgewise Therapeutics
- 13 Feb 2024 According to an Edgewise Therapeutics media release, company expects to report LYNX 3-month controlled dose-ranging data in the second quarter of 2024
- 15 Jan 2024 Planned number of patients changed from 45 to 54.
- 09 Jan 2024 According to an Edgewise Therapeutics media release, the company planned to announce 3-month controlled dose-ranging data in the first half of 2024.